Royal Bank of Canada’s iShares Biotechnology ETF IBB Stock Holding History

Royal Bank of Canada’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-7,500	Closed	-$1.02M	–	7252
2023 Q4	$1.02M	Buy	+7,500	New	+$915K	﹤0.01%	3661
2019 Q3	–	Sell	-400	Closed	-$44K	–	6881
2019 Q2	$44K	Buy	400 +300	+300%	+$31.9K	﹤0.01%	5342
2019 Q1	$11K	Buy	+100	New	+$11K	﹤0.01%	5934
2018 Q1	–	Sell	-67,800	Closed	-$7.24M	–	6535
2017 Q4	$7.24M	Hold	67,800	–	–	﹤0.01%	1818
2017 Q3	$7.54M	Hold	67,800	–	–	﹤0.01%	1719
2017 Q2	$7.01M	Hold	67,800	–	–	﹤0.01%	1741
2017 Q1	$6.63M	Buy	67,800 +47,400	+232%	+$4.54M	﹤0.01%	1733
2016 Q4	$1.8M	Hold	20,400	–	–	﹤0.01%	2663
2016 Q3	$1.97M	Sell	20,400 -579,900	-97%	-$55.2M	﹤0.01%	2567
2016 Q2	$51.5M	Buy	600,300 +543,000	+948%	+$48.7M	0.03%	460
2016 Q1	$4.98M	Buy	57,300 +27,300	+91%	+$2.44M	﹤0.01%	1825
2015 Q4	$3.38M	Buy	+30,000	New	+$3.26M	﹤0.01%	2129
2014 Q2	–	Sell	-60,000	Closed	-$4.73M	–	6023
2014 Q1	$4.73M	Buy	+60,000	New	+$5M	﹤0.01%	1603

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada's IBB Position: Q1 2026 in Review

Royal Bank of Canada increased its iShares Biotechnology ETF (IBB) stake by 1% in Q1 2026, buying an estimated $1.27M and bringing the position to 737,128 shares worth $124M. The position accounts for 0.02% of the portfolio, ranked #567.

Royal Bank of Canada first reported a position in IBB in Q2 2013 and has held it in 52 quarters since. The position peaked at $240M in Q4 2022. 921 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

Royal Bank of Canada held 737,128 shares of iShares Biotechnology ETF worth $124M as of Q1 2026.
Royal Bank of Canada bought 7,434 iShares Biotechnology ETF shares in Q1 2026, an estimated $1.27M.
iShares Biotechnology ETF made up 0.02% of Royal Bank of Canada's portfolio in Q1 2026, its #567 holding.
Royal Bank of Canada first reported a position in iShares Biotechnology ETF in Q2 2013 and has held it in 52 quarters since.
Royal Bank of Canada's iShares Biotechnology ETF position peaked at $240M in Q4 2022.
921 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.